RecruitingNCT05264818

Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma

Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma: a Prospective Single-center Cross-sectional Case-control Study


Sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Enrollment

100 participants

Start Date

May 6, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The glycocalyx is a fibrillary lining structure that covers the inner surface of blood vessels. Composed of glycoproteins and polysaccharides, it is an essential determinant of vascular endothelial physiology: it limits coagulation activation and adapts capillary perfusion. Studies have shown glycocalyx alteration in various vascular and autoimmune pathologies such as diabetes, high blood pressure, chronic renal failure, ischemic heart disease, stroke, dementia, septic shock, and several other inflammatory pathologies with a common basis in vascular insufficiency. Glaucoma is a progressive, chronic and asymptomatic optic neuropathy characterized by visual field damage and abnormalities of the optic nerve head. Two hypotheses have been proposed as a basis for this progressive damage: * the mechanical theory, which explains the papillary excavation by a compression of the optic nerve head under the effect of high intraocular pressure; and * the ischemic theory, explained by a circulatory insufficiency at the level of the blood capillaries of the retina and especially of the optic nerve head. This latter theory is related to several pathologies that have circulatory insufficiency as common underlying pathophysiology, and in which damage to the glycocalyx has been well studied. Glycocalyx damage has rarely been studied in glaucoma. Yang et al. showed that the glycocalyx, present in Schlem's canal, plays a major role in the transduction of shear stress and regulation of outflow resistance to the aqueous humor, which may constitute an interesting biomarker for glaucomatous pathologies.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing the health of the tiny protective lining of blood vessels (called the glycocalyx) in people with primary open-angle glaucoma versus people without glaucoma. Glaucoma is a leading cause of blindness, and researchers suspect that blood vessel damage may play a role in how it develops. **You may be eligible if...** - You are an adult willing to participate - You have been diagnosed with primary open-angle glaucoma in both eyes (for the patient group) - You have no optic nerve disease or glaucoma (for the healthy control group) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have sleep apnea, kidney failure, Parkinson's disease, or Alzheimer's disease - You have had a stroke in the past year or a heart attack in the past year - You have had cancer treated within the last 2 years - You have antiphospholipid syndrome (a blood clotting disorder) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREGlycocheck

Assessment of the sublingual microvascularization

PROCEDUREOphthalmological examinations

Description : Measurement of best corrected distance visual acuity with ETDRS (Early Treatment Diabetic Retinopathy Study) Measurement of intraocular pressure by aplanation and forced air tonometer Central corneal thickness measurement with OCT (Optical Coherence Tomography) Non-mydriatic retinophotography Humphrey 24-2 visual field OCT-RNFL (Optical Coherence Tomography - retinal nerve fiber layer)


Locations(1)

Hôpital Fondation A. de Rothschild

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05264818


Related Trials